Almirall has announced that Invida Holdings has licensed the rights to market aclidinium bromide inhalers for the treatment of COPD in Australia and New Zealand. The deal covers Genuair DPIs with aclidinium alone and a combination with formoterol that is still in development.
Aclidinium will be the first respiratory product for Invida, which was acquired by Menarini in 2011. Earlier this year, Almirall licensed rights to the product in most of Europe to Menarini, which will market the inhaler under the name Bretaris Genuair.
Almirall CEO Eduardo Sanchiz said, “In partnership with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD, a disease increasing in prevalence that causes mortality and poor quality of life. With this new agreement aclidinium, via partners or Almirall’s own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe.”
Read the Almirall press release.
